1-20 of 28
Seiji Yano
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers

Yuki Katayama, Tadaaki Yamada, Keiko Tanimura, Hayato Kawachi, Masaki Ishida, Yohei Matsui, Soichi Hirai, Ryota Nakamura, Kenji Morimoto, Naoki Furuya, Sachiko Arai, Yasuhiro Goto, Yoshihiko Sakata, Kazumi Nishino, Michiko Tsuchiya, Akihiro Tamiya, Go Saito, Satoshi Muto, Takayuki Takeda, Koji Date, Yasuhito Fujisaka, Satoshi Watanabe, Daichi Fujimoto, Hisanori Uehara, Mano Horinaka, Toshiyuki Sakai, Seiji Yano, Shinsaku Tokuda, Koichi Takayama
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF15.
https://doi.org/10.1158/1078-0432.CCR-24-1762
Published: 27 November 2024
View article titled, YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
Open the PDF for YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers in another window
Includes: Supplementary data
Journal Articles

Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression

Azusa Tanimoto, Shingo Matsumoto, Shinji Takeuchi, Sachiko Arai, Koji Fukuda, Akihiro Nishiyama, Kiyotaka Yoh, Takaya Ikeda, Naoki Furuya, Kazumi Nishino, Yuichiro Ohe, Koichi Goto, Seiji Yano
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (5): 1410–1420.
https://doi.org/10.1158/1078-0432.CCR-20-2853
Published: 01 March 2021
View article titled, Proteasome Inhibition Overcomes ALK-TKI Resistance in <em>ALK</em>-Rearranged/<em>TP53</em>-Mutant NSCLC via Noxa Expression
Open the PDF for Proteasome Inhibition Overcomes ALK-TKI Resistance in <em>ALK</em>-Rearranged/<em>TP53</em>-Mutant NSCLC via Noxa Expression in another window
Includes: Supplementary data
Journal Articles

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer

Naoko Okura, Naoya Nishioka, Tadaaki Yamada, Hirokazu Taniguchi, Keiko Tanimura, Yuki Katayama, Akihiro Yoshimura, Satoshi Watanabe, Toshiaki Kikuchi, Shinsuke Shiotsu, Takeshi Kitazaki, Akihiro Nishiyama, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Hisanori Uehara, Mano Horinaka, Toshiyuki Sakai, Kohei Tanaka, Ryohei Kozaki, Seiji Yano, Koichi Takayama
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2244–2256.
https://doi.org/10.1158/1078-0432.CCR-19-2321
Published: 01 May 2020
View article titled, ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in <em>EGFR</em>-Mutated Non–Small Cell Lung Cancer
Open the PDF for ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in <em>EGFR</em>-Mutated Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract A36: Establishment of patient-derived xenograft models of lung adenocarcinoma with two different EGFR mutations, L858R and exon19 deletion

Kenji Kita, Koji Fukuda, Akihiro Nishiyama, Sachiko Arai, Shinji Takeuchi, Koushiro Ohtsubo, Kaname Yamashita, Masaya Tamura, Isao Matsumoto, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17_Supplement): A36.
https://doi.org/10.1158/1557-3265.AACRIASLC18-A36
Published: 01 September 2018
View article titled, Abstract A36: Establishment of patient-derived xenograft models of lung adenocarcinoma with two different EGFR mutations, L858R and exon19 deletion
Journal Articles

Abstract B02: Heterogeneity of epithelial-to-mesenchymal transition and resistance mutation in ALK inhibitor-resistant lung cancer and its circumvention

Koji Fukuda, Shinji Takeuchi, Sachiko Arai, Ryohei Katayama, Shigeki Nanjo, Azusa Tanimoto, Akihiro Nisiyama, Takeshi Suzuki, Kengo Takeuchi, Makoto Nishio, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17_Supplement): B02.
https://doi.org/10.1158/1557-3265.AACRIASLC18-B02
Published: 01 September 2018
View article titled, Abstract B02: Heterogeneity of epithelial-to-mesenchymal transition and resistance mutation in ALK inhibitor-resistant lung cancer and its circumvention
Journal Articles

Abstract PR13: MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer

Shigeki Nanjo, Sachiko Arai, Wei Wang, Akito Hata, Nobuyuki Katakami, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (17_Supplement): PR13.
https://doi.org/10.1158/1557-3265.AACRIASLC18-PR13
Published: 01 September 2018
View article titled, Abstract PR13: MET copy number gain is associated with gefitinib resistance in leptomeningeal carcinomatosis of EGFR-mutant lung cancer
Journal Articles

Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion–Positive Tumor Cells in a Brain Metastasis Model

Akihiro Nishiyama, Tadaaki Yamada, Kenji Kita, Rong Wang, Sachiko Arai, Koji Fukuda, Azusa Tanimoto, Shinji Takeuchi, Shoichiro Tange, Atsushi Tajima, Noritaka Furuya, Takayoshi Kinoshita, Seiji Yano
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (10): 2357–2369.
https://doi.org/10.1158/1078-0432.CCR-17-1623
Published: 14 May 2018
View article titled, Foretinib Overcomes Entrectinib Resistance Associated with the <em>NTRK1</em> G667C Mutation in <em>NTRK1</em> Fusion–Positive Tumor Cells in a Brain Metastasis Model
Open the PDF for Foretinib Overcomes Entrectinib Resistance Associated with the <em>NTRK1</em> G667C Mutation in <em>NTRK1</em> Fusion–Positive Tumor Cells in a Brain Metastasis Model in another window
Includes: Supplementary data
Journal Articles

Histone Deacetylase 3 Inhibition Overcomes BIM Deletion Polymorphism–Mediated Osimertinib Resistance in EGFR-Mutant Lung Cancer

Azusa Tanimoto, Shinji Takeuchi, Sachiko Arai, Koji Fukuda, Tadaaki Yamada, Xavier Roca, S. Tiong Ong, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (12): 3139–3149.
https://doi.org/10.1158/1078-0432.CCR-16-2271
Published: 14 June 2017
View article titled, Histone Deacetylase 3 Inhibition Overcomes <em>BIM</em> Deletion Polymorphism–Mediated Osimertinib Resistance in <em>EGFR-</em>Mutant Lung Cancer
Open the PDF for Histone Deacetylase 3 Inhibition Overcomes <em>BIM</em> Deletion Polymorphism–Mediated Osimertinib Resistance in <em>EGFR-</em>Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract PR7: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells

Seiji Yano, Shinji Takeuchi, Takayuki Nakagawa, Tadaaki Yamada
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): PR7.
https://doi.org/10.1158/1078-0432.MECHRES-PR7
Published: 04 March 2013
View article titled, Abstract PR7: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells
Open the PDF for Abstract PR7: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor-resistance in EML4-ALK lung cancer cells in another window
Journal Articles

Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells

Tadaaki Yamada, Shinji Takeuchi, Junya Nakade, Kenji Kita, Takayuki Nakagawa, Shigeki Nanjo, Takahiro Nakamura, Kunio Matsumoto, Manabu Soda, Hiroyuki Mano, Toshimitsu Uenaka, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (13): 3592–3602.
https://doi.org/10.1158/1078-0432.CCR-11-2972
Published: 01 July 2012
View article titled, Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells
Open the PDF for Paracrine Receptor Activation by Microenvironment Triggers Bypass Survival Signals and ALK Inhibitor Resistance in EML4-ALK Lung Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer

Wei Wang, Qi Li, Shinji Takeuchi, Tadaaki Yamada, Hitomi Koizumi, Takahiro Nakamura, Kunio Matsumoto, Naofumi Mukaida, Yasuhiko Nishioka, Saburo Sone, Takayuki Nakagawa, Toshimitsu Uenaka, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1663–1671.
https://doi.org/10.1158/1078-0432.CCR-11-1171
Published: 14 March 2012
View article titled, Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in <em>EGFR</em> Mutant Lung Cancer
Open the PDF for Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor–Induced Tyrosine Kinase Inhibitor Resistance in <em>EGFR</em> Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract B21: E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells

Takayuki Nakagawa, Shinji Takeuchi, Tadaaki Yamada, Kenji Kita, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (3_Supplement): B21.
https://doi.org/10.1158/1078-0432.12AACRIASLC-B21
Published: 01 February 2012
View article titled, Abstract B21: E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells
Open the PDF for Abstract B21: E7050, a Met kinase inhibitor, reverses three different mechanisms of hepatocyte growth factor-induced resistance to tyrosine kinase inhibitors in EGFR mutant lung cancer cells in another window
Journal Articles

The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer

Kazuo Yasumoto, Tadaaki Yamada, Atsuhiro Kawashima, Wei Wang, Qi Li, Ivan Shterev Donev, Shinji Tacheuchi, Hisatsugu Mouri, Kaname Yamashita, Koushiro Ohtsubo, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (11): 3619–3630.
https://doi.org/10.1158/1078-0432.CCR-10-2475
Published: 01 June 2011
View article titled, The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer
Open the PDF for The EGFR Ligands Amphiregulin and Heparin-Binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-Expressing Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer

Ivan S. Donev, Wei Wang, Tadaaki Yamada, Qi Li, Shinji Takeuchi, Kunio Matsumoto, Takao Yamori, Yasuhiko Nishioka, Saburo Sone, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2260–2269.
https://doi.org/10.1158/1078-0432.CCR-10-1993
Published: 14 April 2011
View article titled, Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in <em>EGFR</em> Mutant Lung Cancer
Open the PDF for Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in <em>EGFR</em> Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

Tadaaki Yamada, Kunio Matsumoto, Wei Wang, Qi Li, Yasuhiko Nishioka, Yoshitaka Sekido, Saburo Sone, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (1): 174–183.
https://doi.org/10.1158/1078-0432.CCR-09-1204
Published: 04 January 2010
View article titled, Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in <em>EGFR</em>-T790M Mutant Lung Cancer
Open the PDF for Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in <em>EGFR</em>-T790M Mutant Lung Cancer in another window
Includes: Supplementary data
Journal Articles

E7080, a Multi–Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles

Kenji Ikuta, Seiji Yano, Van The Trung, Masaki Hanibuchi, Hisatsugu Goto, Qi Li, Wei Wang, Tadaaki Yamada, Hirokazu Ogino, Soji Kakiuchi, Hisanori Uehara, Yoshitaka Sekido, Toshimitsu Uenaka, Yasuhiko Nishioka, Saburo Sone
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (23): 7229–7237.
https://doi.org/10.1158/1078-0432.CCR-09-1980
Published: 30 November 2009
View article titled, E7080, a Multi–Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles
Open the PDF for E7080, a Multi–Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles in another window
Journal Articles

Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Wei Wang, Qi Li, Tadaaki Yamada, Kunio Matsumoto, Isao Matsumoto, Makoto Oda, Go Watanabe, Yoshiyuki Kayano, Yasuhiko Nishioka, Saburo Sone, Seiji Yano
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (21): 6630–6638.
https://doi.org/10.1158/1078-0432.CCR-09-1001
Published: 02 November 2009
View article titled, Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Open the PDF for Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in another window
Includes: Supplementary data
Journal Articles

Follistatin Suppresses the Production of Experimental Multiple-Organ Metastasis by Small Cell Lung Cancer Cells in Natural Killer Cell–Depleted SCID Mice

Hirokazu Ogino, Seiji Yano, Soji Kakiuchi, Hiroaki Muguruma, Kenji Ikuta, Masaki Hanibuchi, Hisanori Uehara, Kunihiro Tsuchida, Hiromu Sugino, Saburo Sone
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (3): 660–667.
https://doi.org/10.1158/1078-0432.CCR-07-1221
Published: 01 February 2008
View article titled, Follistatin Suppresses the Production of Experimental Multiple-Organ Metastasis by Small Cell Lung Cancer Cells in Natural Killer Cell–Depleted SCID Mice
Open the PDF for Follistatin Suppresses the Production of Experimental Multiple-Organ Metastasis by Small Cell Lung Cancer Cells in Natural Killer Cell–Depleted SCID Mice in another window
Journal Articles

The Therapeutic Efficacy of Anti–Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice

Qi Li, Seiji Yano, Hirokazu Ogino, Wei Wang, Hisanori Uehara, Yasuhiko Nishioka, Saburo Sone
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19): 5918–5925.
https://doi.org/10.1158/1078-0432.CCR-07-0501
Published: 01 October 2007
View article titled, The Therapeutic Efficacy of Anti–Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice
Open the PDF for The Therapeutic Efficacy of Anti–Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice in another window
Journal Articles

Reveromycin A Inhibits Osteolytic Bone Metastasis of Small-Cell Lung Cancer Cells, SBC-5, through an Antiosteoclastic Activity

Hiroaki Muguruma, Seiji Yano, Soji Kakiuchi, Hisanori Uehara, Makoto Kawatani, Hiroyuki Osada, Saburo Sone
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (24): 8822–8828.
https://doi.org/10.1158/1078-0432.CCR-05-1335
Published: 16 December 2005
View article titled, Reveromycin A Inhibits Osteolytic Bone Metastasis of Small-Cell Lung Cancer Cells, SBC-5, through an Antiosteoclastic Activity
Open the PDF for Reveromycin A Inhibits Osteolytic Bone Metastasis of Small-Cell Lung Cancer Cells, SBC-5, through an Antiosteoclastic Activity in another window
Includes: Supplementary data